Biotech

All Articles

Vaxcyte climbs on 'impressive' 31-valent PCV gain against Pfizer

.Vaxcyte revealed what professionals referred to as "impressive" phase 1/2 records for its 31-valent...

Recursion's brain disease trial presents insufficient evidence of efficacy

.Recursion has stumbled through an early examination of its own tech-enabled technique to medication...

Acepodia, Pfizer click all together for chemistry-based cell therapy

.Phone it a situation of excellent chemical make up: Acepodia, a biotech based on Nobel Champion sci...

Praxis epilepsy medicine lowers seizures in phase 2 hearing

.Practice Preciseness Medicines has actually racked up one more midphase win in epilepsy this year, ...

Three execs surrender as Dyne messages blended data for DMD prospect

.After getting away a professional hold several years back, Dyne Therapy has exposed brand new perio...

Arrowhead fires off phase 3 information in rare metabolic ailment in front of market encounter Ionis

.Arrowhead Pharmaceuticals has actually presented its give before a potential showdown along with Io...

Pfizer, Valneva present lyme disease chance reliable for second enhancer

.Pfizer and Valneva may have concerning two additional years to stand by before they produce the ini...

Fierce Biotech Managing Editor Ayla Ellison Talks Shop with Michelle Benz on the Future of Biotech.

.Permit's study a talk with Ayla Ellison, Tough Biotech Editor-in-Chief as well as Michelle Benz as ...

New records demonstrate how Bayer's asundexian failed to prevent strokes

.Bayer put on hold the phase 3 trial for its own variable XIa prevention asundexian late last year a...

Sanofi's tolebrutinib stops working 2 of 3 late-stage MS trials

.Sanofi is still set on taking its a number of sclerosis (MS) med tolebrutinib to the FDA, execs hav...